MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 225 filers reported holding MYRIAD GENETICS INC in Q3 2017. The put-call ratio across all filers is 1.94 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $325,405 | +59.5% | 14,008 | +90.0% | 0.01% | +120.0% |
Q4 2021 | $204,000 | -0.5% | 7,374 | +10.2% | 0.01% | -16.7% |
Q2 2021 | $205,000 | -93.6% | 6,689 | -92.2% | 0.01% | -95.3% |
Q2 2018 | $3,222,000 | +30.8% | 86,231 | +1.5% | 0.13% | +27.0% |
Q1 2018 | $2,464,000 | -37.7% | 84,938 | -26.2% | 0.10% | -43.8% |
Q4 2017 | $3,954,000 | +1.1% | 115,121 | +6.5% | 0.18% | -16.0% |
Q3 2017 | $3,911,000 | -2.4% | 108,092 | -30.3% | 0.21% | -36.1% |
Q2 2017 | $4,007,000 | +36.9% | 155,067 | +1.7% | 0.33% | +14.1% |
Q1 2017 | $2,927,000 | +88.2% | 152,426 | +200.0% | 0.29% | +32.9% |
Q2 2016 | $1,555,000 | -58.4% | 50,802 | -49.1% | 0.22% | -5.2% |
Q1 2016 | $3,738,000 | +77.4% | 99,882 | +104.6% | 0.23% | -13.2% |
Q4 2015 | $2,107,000 | +185.5% | 48,817 | +147.9% | 0.27% | +160.8% |
Q3 2015 | $738,000 | +29.5% | 19,689 | +17.3% | 0.10% | +34.2% |
Q2 2015 | $570,000 | +1.4% | 16,781 | +5.7% | 0.08% | -32.7% |
Q1 2015 | $562,000 | +17.6% | 15,873 | +13.0% | 0.11% | -29.8% |
Q4 2014 | $478,000 | – | 14,047 | – | 0.16% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 5,000,000 | $90,850,000 | 3.94% |
Altium Capital Management LP | 221,000 | $4,016,000 | 1.61% |
DISCIPLINED GROWTH INVESTORS INC /MN | 1,900,787 | $34,537,000 | 0.93% |
Zebra Capital Management LLC | 15,352 | $279,000 | 0.82% |
PFM Health Sciences, LP | 1,177,250 | $21,391,000 | 0.82% |
EARNEST PARTNERS LLC | 6,462,138 | $117,417,000 | 0.78% |
Glenview Capital Management | 1,696,791 | $30,831,000 | 0.77% |
AIMZ Investment Advisors, LLC | 42,085 | $765,000 | 0.37% |
Phocas Financial Corp. | 127,949 | $2,325,000 | 0.35% |
Redhawk Wealth Advisors, Inc. | 34,680 | $630,000 | 0.29% |